Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Wolfe Research

Oruka Therapeutics (NASDAQ:ORKA) was upgraded by stock analysts at Wolfe Research to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Other analysts have also recently issued research reports about the stock. Wedbush reaffirmed an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, December 20th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Oruka Therapeutics presently has a consensus rating of “Buy” and an average price target of $39.86.

Oruka Therapeutics Trading Up 3.7 %

Shares of Oruka Therapeutics stock opened at $14.21 on Monday. The company has a market capitalization of $497.35 million, a PE ratio of -2.27 and a beta of 0.77. The business has a fifty day simple moving average of $18.09. Oruka Therapeutics has a twelve month low of $10.95 and a twelve month high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. AlphaCentric Advisors LLC purchased a new stake in Oruka Therapeutics in the 4th quarter valued at about $119,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $144,000. Franklin Resources Inc. purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $17,661,000. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $343,000. Finally, Frazier Life Sciences Management L.P. purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $11,699,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.